Investor Relations

Vaccine delivery based on unique TET-platform

Contact us

About Immuneed

Our vision is to provide breakthrough, tumor-directed immunotherapeutics to areas with high unmet medical needs and where an immune-mediated anti-tumor response can make a difference by improving anti-tumor efficacy and reducing immune-related side effects. Immuneed is in premises with fully integrated infrastructure and lab capabilities in Uppsala, Sweden.

Why invest in us?

We have developed a proprietary technology platform, the TET-platform™, which can be used for multiple indications. Focus with our first drug candidate is early stage intermediate to high-risk prostate cancer. The unique composition of our vaccine complex allows us to create the next generation synthetic peptide vaccine products. Initial seed funding is secured, but further funding is needed early 2018.

To learn more about investment opportunities:

Quick Links

Dag Hammarskjölds väg 13a | 752 37 Uppsala, Sweden |